Related Experiment Videos
Preliminary experience with the implantable transvenous cardioverter
Pacing and Clinical Electrophysiology : PACE
|November 1, 1984
Summary
A novel implantable device effectively terminates ventricular tachycardia using synchronized shocks. This small, implantable device also offers pacing and electrophysiologic study capabilities.
Area of Science:
- Cardiovascular Medicine
- Medical Devices
- Electrophysiology
Background:
- Sustained ventricular tachycardia (VT) is a life-threatening arrhythmia.
- Current treatment options for VT include antiarrhythmic drugs and invasive procedures.
- There is a need for effective, implantable solutions for VT management.
Purpose of the Study:
- To evaluate the efficacy of a novel implantable device for terminating sustained ventricular tachycardia.
- To assess the feasibility and safety of implanting this device.
- To explore the device's additional capabilities, including VVI pacing and electrophysiologic studies.
Main Methods:
- A synchronized shock (≤2.0 joules) delivered via a specialized catheter electrode to the right ventricle apex.
- Implantation of a 95-gram device under lidocaine anesthesia.
- Monitoring of device performance in terminating VT in canine models and human patients.
Main Results:
- The device effectively terminated sustained ventricular tachycardia in both dogs and patients.
- The implant procedure was well-tolerated under lidocaine anesthesia.
- The device demonstrated concurrent capabilities for VVI pacing and programmed electrophysiologic studies.
Conclusions:
- The novel implantable device offers a promising approach for terminating ventricular tachycardia.
- The device is safe, effective, and versatile, with potential for broader application in arrhythmia management.